Benefits

Dashboard

See Price & Plans

Not registered yet? Get a free account.

Biocon Biologics Limited
Location
People
Financials
- Financial Highlights
- Balance Sheet
- Profit & Loss
- Ratios
Charges
Network
T. Score
Registered Details

BIOCON BIOLOGICS LIMITED

All Companies ›

Karnataka ›

Manufacturing of Chemical Products ›

Active

Updated: 23 Mar 2026

Biocon Biologics Limited is a global biopharmaceutical company that specializes in the development and manufacture of biosimilars and biologics. It provides a range of therapeutic products, including monoclonal antibodies and insulin formulations, aimed at treating chronic diseases and improving patient access to high-quality medicines.

Biocon Biologics Limited, is an unlisted public company incorporated on 08 June, 2016. It is classified as a public limited company and is located in , Karnataka. It's authorized share capital is INR 3,500.00 cr and the total paid-up capital is INR 1,758.31 cr.

Subscription Plans

Industry and products

Manufacturing (Chemicals and chemical products)

Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

Company size

Auth Capital

₹ 3,500.0 Cr

Paidup Capital

₹ 1,758.3 Cr

Revenue

₹ 3750-4000 cr

Key Metrics

** All rupee values in INR crores. Based on March 2024 numbers.

Total Revenue

72.42%

₹ 3,774.7

EBITDA

₹ 290.1

Net Profit

₹ 368.9

Networth

3.82%

₹ 17,426.0

Borrowings

29.93%

₹ 5,013.9

Assets

7.84%

₹ 24,534.4

Gross Margin

3.25

65.8 %

Operating Margin

22.08

9.4 %

Net Profit Margin

30.11

9.8 %

Return on Equity

4.77

2.1 %

ROCE

14.68

0.5 %

Debt to Equity

0.06

0.3

Sales

Mar 2024

Net worth

Mar 2024

Buy Report or Plans

Dashboards

Popular Plan

Company dashboard

₹ 449
- Five year financials and ratios
- Risk analysis
- Interactive charts

Buy credits

View subscriptions

MCA Fillings

All financials

₹ 349
- All financials
- All annual returns
- MoA and AoA
1 Year

₹ 249
- Latest financials
- Latest annual return
- MoA and AoA

PDF Reports

Financial report

₹ 799
- Five year financials and ratios
- Shareholding and group structure
Financial+Litigation report

₹ 1299
- Everything in financial report
- Litigation report on the company
Due diligence report

₹ 2999
- Everything in financial+litigation report
- Peers and financials

* GST not included

** Reports & MCA filings will be based on the latest available financials.

** Delivery timelines are on best-effort basis during working hours. Filings 3-4 hours. Reports 24-48 hours.

Locations

India (22)

State	Type	Address

Locations on Map

People

Designation	Name	DIN/PAN	Tenure
Director	Thomas Jason Roberts	09337723	4 years
Director	Daniel Mark Bradbury	06599933	7 years
Director	Nivruti Rai	01353079	7 years
Director	Bobby Kanubhai Parikh Shareholder	00019437	7 years
Director	Peter Baron Piot	09015343	5 years
Whole-time Director	Kiran Mazumdar Shaw	00347229	10 years
Director	Arun Suresh Chandavarkar Shareholder	01596180	10 years
Managing Director	Shreehas Pradeep Tambe	09796480	3 years
Nominee Director	Rajiv Malik	00120557	3 years

Financial Highlights

** All numbers in INR crores

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Sales	1,768.8	1,940.8	2,362.5	2,092.4	3,093.3
Operating profit	443.6	405.1	376.7	-265.8	290.1
Net profit	288.3	209.7	86.0	-445.3	368.9
Gross margin	70.7	67.6	66.3	62.5	65.8
Operating margin	25.1	20.9	15.9	-12.7	9.4
Net margin	16.1	10.8	3.6	-20.3	9.8
Networth	1,015.3	2,049.3	2,120.6	16,785.6	17,426.0
Borrowings	838.3	2,406.5	4,230.9	3,859.0	5,013.9
Assets	4,898.9	6,843.4	7,353.9	22,749.9	24,534.4
Debt to equity	0.8	1.2	2.0	0.2	0.3
Current ratio	0.6	1.0	0.9	1.2	1.1
ROE	28.4	10.2	4.1	-2.6	2.1
Days payable	360.0	309.0	225.0	415.0	198.0
WC days	-260.0	-15.0	-55.0	67.0	42.0

Margins

Gross margin

Operating margin

Net margin

Balance Sheet

Standalone

Consolidated

₹

** All numbers in INR crores

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	206.0	1,058.8	1,058.8	1,321.7	1,321.7
Reserves	809.3	990.5	1,061.8	15,463.9	16,104.3
Borrowings +	838.3	2,406.5	4,230.9	3,859.0	5,013.9
Long term borrowings	565.0	2,128.3	2,353.8	2,774.8	2,928.2
Short term borrowings	273.3	278.2	1,877.1	1,084.2	2,085.7
Trade payables +	511.3	532.6	489.2	892.6	575.0
Days payable	360.0	309.0	225.0	415.0	198.0
Other liabilities +	2,534.0	1,855.0	513.2	1,212.7	1,519.5
Other non-current liabilities	316.7	308.5	299.5	959.0	1,118.7
Other current liabilities	2,217.3	1,546.5	213.7	253.7	400.8
Total liabilities	4,898.9	6,843.4	7,353.9	22,749.9	24,534.4
Fixed Assets +	1,838.8	2,453.7	2,996.9	3,097.3	3,304.1
Tangible assets	677.7	852.3	874.0	2,024.2	1,966.9
CWIP	1,152.6	1,592.4	2,095.2	1,057.1	1,222.8
Intangible assets	8.5	9.0	27.7	16.0	114.4
LT loans and advances	-	-	-	-	-
Other non-current assets	1,318.9	2,114.3	2,135.4	17,039.0	17,813.6
Current assets +	1,741.2	2,275.4	2,221.6	2,613.6	3,416.7
Inventories	542.8	907.4	984.0	1,550.9	1,427.7
Trade receivables	919.2	266.9	847.7	582.7	1,632.2
Cash and cash equivalents	154.0	189.1	62.8	120.2	86.4
ST loans and advances	-	-	-	-	-
Other current assets	125.2	912.0	327.1	359.8	270.4
Total assets	4,898.9	6,843.4	7,353.9	22,749.9	24,534.4

Percentage of assets	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	4.21	15.47	14.4	5.81	5.39
Reserves	16.52	14.47	14.44	67.97	65.64
Borrowings +	17.11	35.17	57.53	16.96	20.44
Long term borrowings	11.53	31.1	32.01	12.2	11.94
Short term borrowings	5.58	4.07	25.53	4.77	8.5
Trade payables	10.44	7.78	6.65	3.92	2.34
Other liabilities +	62.16	34.89	13.63	9.25	8.54
Other non-current liabilities	6.46	4.51	4.07	4.22	4.56
Other current liabilities	45.26	22.6	2.91	1.12	1.63
Total liabilities
Fixed Assets +	37.53	35.85	40.75	13.61	13.47
Tangible assets	13.83	12.45	11.88	8.9	8.02
CWIP	23.53	23.27	28.49	4.65	4.98
Intangible assets	0.17	0.13	0.38	0.07	0.47
LT loans and advances	0.0	0.0	0.0	0.0	0.0
Other non-current assets	26.92	30.9	29.04	74.9	72.61
Current assets +	35.54	33.25	30.21	11.49	13.93
Inventories	11.08	13.26	13.38	6.82	5.82
Trade receivables	18.76	3.9	11.53	2.56	6.65
Cash and cash equivalents	3.14	2.76	0.85	0.53	0.35
ST loans and advances	0.0	0.0	0.0	0.0	0.0
Other current assets	2.56	13.33	4.45	1.58	1.1
Total assets

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	206.0	1,058.8	1,058.8	1,321.7	1,321.7
Reserves	539.6	722.3	1,152.0	16,285.9	17,019.2
Borrowings +	1,891.4	2,795.0	5,062.3	14,482.3	13,892.0
Long term borrowings	1,570.3	2,460.7	3,166.4	13,262.6	11,217.2
Short term borrowings	321.1	334.3	1,895.9	1,219.7	2,674.8
Trade payables +	717.7	931.4	904.4	3,238.1	5,680.6
Days payable	522.0	469.0	329.0	737.0	759.0
Other liabilities +	3,689.6	3,565.5	1,517.6	4,836.8	5,195.7
Other non-current liabilities	1,071.4	1,082.4	1,201.6	3,935.9	1,595.6
Other current liabilities	2,618.2	2,483.1	316.0	900.9	3,600.1
Total liabilities	7,044.3	9,073.0	9,695.1	40,164.8	43,109.2
Fixed Assets +	4,798.1	5,480.1	6,153.3	31,820.6	32,236.5
Tangible assets	2,639.7	2,627.1	2,594.1	3,819.8	3,853.1
CWIP	1,776.1	2,269.2	3,008.8	6,141.5	5,823.2
Intangible assets	382.3	583.8	550.4	21,859.3	22,560.2
LT loans and advances	-	-	-	-	-
Other non-current assets	319.8	368.0	351.8	1,418.3	780.4
Current assets +	1,926.4	3,224.9	3,190.0	6,925.9	10,092.3
Inventories	786.4	1,243.7	1,410.5	3,160.7	3,709.2
Trade receivables	326.8	404.0	878.0	2,344.3	4,950.5
Cash and cash equivalents	224.1	202.2	144.4	859.0	853.4
ST loans and advances	-	-	-	-	-
Other current assets	589.1	1,375.0	757.1	561.9	579.2
Total assets	7,044.3	9,073.0	9,695.1	40,164.8	43,109.2

Percentage of assets	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	2.92	11.67	10.92	3.29	3.07
Reserves	7.66	7.96	11.88	40.55	39.48
Borrowings +	26.85	30.81	52.22	36.06	32.23
Long term borrowings	22.29	27.12	32.66	33.02	26.02
Short term borrowings	4.56	3.68	19.56	3.04	6.2
Trade payables	10.19	10.27	9.33	8.06	13.18
Other liabilities +	62.57	49.56	24.98	20.1	25.23
Other non-current liabilities	15.21	11.93	12.39	9.8	3.7
Other current liabilities	37.17	27.37	3.26	2.24	8.35
Total liabilities
Fixed Assets +	68.11	60.4	63.47	79.23	74.78
Tangible assets	37.47	28.96	26.76	9.51	8.94
CWIP	25.21	25.01	31.03	15.29	13.51
Intangible assets	5.43	6.43	5.68	54.42	52.33
LT loans and advances	0.0	0.0	0.0	0.0	0.0
Other non-current assets	4.54	4.06	3.63	3.53	1.81
Current assets +	27.35	35.54	32.9	17.24	23.41
Inventories	11.16	13.71	14.55	7.87	8.6
Trade receivables	4.64	4.45	9.06	5.84	11.48
Cash and cash equivalents	3.18	2.23	1.49	2.14	1.98
ST loans and advances	0.0	0.0	0.0	0.0	0.0
Other current assets	8.36	15.15	7.81	1.4	1.34
Total assets

Total assets

Profit & Loss

Standalone

Consolidated

₹

** All numbers in INR crores

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Sales +	1,768.8	1,940.8	2,362.5	2,092.4	3,093.3
Sales growth %	None	9.72	21.73	-11.43	47.84
Expenses +	1,463.9	1,690.9	2,200.1	2,710.6	3,333.9
Cost of goods	517.7	628.9	795.0	784.5	1,059.1
Employee cost	372.9	423.5	539.9	631.1	742.6
Other costs	434.6	483.3	650.9	942.6	1,001.5
Operating profit +	443.6	405.1	376.7	-265.8	290.1
Operating margin %	25.1	20.9	15.9	-12.7	9.4
Other income	22.3	6.3	10.3	96.9	681.4
Interest	32.1	36.9	59.1	124.3	258.5
Depreciation	106.6	118.3	155.2	228.1	272.2
Exceptional items	-3.8	-12.1	-80.4	-3.8	-8.2
Profit before tax	323.4	244.1	92.3	-525.1	432.6
Tax	35.1	34.4	6.3	-79.8	63.7
Profit - disc. ops	-	-	-	-	-
Net profit	288.3	209.7	86.0	-445.3	368.9
Net margin %	16.1	10.8	3.6	-20.3	9.8

Precentage of total income	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Sales	98.75	99.68	99.57	95.57	81.95
Expenses +	81.73	86.84	92.72	123.81	88.32
Cost of goods	28.9	32.3	33.5	35.83	28.06
Employee cost	20.82	21.75	22.75	28.83	19.67
Other costs	24.26	24.82	27.43	43.05	26.53
Operating profit	24.77	20.81	15.88	-12.14	7.69
Other income	1.25	0.32	0.43	4.43	18.05
Interest	1.79	1.9	2.49	5.68	6.85
Depreciation	5.95	6.08	6.54	10.42	7.21
Exceptional items	-0.21	-0.62	-3.39	-0.17	-0.22
Profit before tax	18.06	12.54	3.89	-23.98	11.46
Tax	1.96	1.77	0.27	-3.65	1.69
Profit - disc. ops	0.0	0.0	0.0	0.0	0.0
Net profit	16.1	10.77	3.62	-20.34	9.77

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Sales +	2,305.5	2,797.2	3,464.3	5,583.8	8,824.2
Sales growth %	21.63	21.33	23.85	61.18	58.03
Expenses +	1,910.8	2,439.0	2,931.5	5,192.8	8,704.9
Cost of goods	501.9	725.4	1,003.7	1,602.8	2,732.1
Employee cost	504.4	610.6	716.9	848.8	1,270.2
Other costs	557.6	722.8	741.2	1,806.1	2,808.7
Operating profit +	741.6	738.4	1,002.5	1,326.1	2,013.2
Operating margin %	32.2	26.4	28.9	23.8	22.8
Other income	26.5	6.4	10.4	12.0	176.4
Interest	82.8	37.2	66.8	296.9	863.7
Depreciation	264.1	343.0	402.9	638.2	1,030.2
Exceptional items	-3.8	-22.6	-80.4	-284.4	16.6
Profit before tax	417.4	342.0	462.8	118.6	312.3
Tax	100.1	74.5	80.3	-14.9	94.1
Profit - disc. ops	-	-	-	-	-
Net profit	317.3	267.5	382.5	133.5	218.2
Net margin %	13.6	9.5	11.0	2.4	2.4

Precentage of total income	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Sales	98.86	99.77	99.7	99.79	98.04
Expenses +	81.94	87.0	84.37	92.8	96.71
Cost of goods	21.52	25.87	28.89	28.64	30.35
Employee cost	21.63	21.78	20.63	15.17	14.11
Other costs	23.91	25.78	21.33	32.28	31.21
Operating profit	31.8	26.34	28.85	23.7	22.37
Other income	1.14	0.23	0.3	0.21	1.96
Interest	3.55	1.33	1.92	5.31	9.6
Depreciation	11.33	12.23	11.6	11.4	11.45
Exceptional items	-0.16	-0.81	-2.31	-5.08	0.18
Profit before tax	17.9	12.2	13.32	2.12	3.47
Tax	4.29	2.66	2.31	-0.27	1.05
Profit - disc. ops	0.0	0.0	0.0	0.0	0.0
Net profit	13.61	9.54	11.01	2.39	2.42

Revenue from operations

Ratios

Standalone

Consolidated

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Solvency +
Total Debt/Equity	0.8	1.2	2.0	0.2	0.3
Net Debt/Equity	0.7	1.1	2.0	0.2	0.3
Total Debt/Assets	0.2	0.3	0.6	0.2	0.2
Total Assets/Equity	4.8	3.3	3.5	1.4	1.4
Liquidity +
Current Ratio	0.6	1.0	0.9	1.2	1.1
Quick Ratio	0.4	0.6	0.5	0.5	0.7
Interest Coverage	13.8	11.0	6.4	-2.1	1.1
Performance
Gross Margin	70.7	67.6	66.3	62.5	65.8
Operating Margin	25.1	20.9	15.9	-12.7	9.4
Net Margin	16.1	10.8	3.6	-20.3	9.8
Return +
Return on Equity	28.4	10.2	4.1	-2.6	2.1
Pre-tax ROCE	58.3	12.1	8.4	-14.2	0.5
Return on Assets	5.9	3.1	1.2	-2.0	1.5
Pre-tax ROIC	19.8	6.7	3.5	-2.4	0.1
Efficiency +
Days Payable	360.0	309.0	225.0	415.0	198.0
Days Inventory	383.0	527.0	452.0	722.0	492.0
Days Receivable	190.0	50.0	131.0	102.0	193.0
Fixed Asset Turnover	1.0	0.8	0.8	0.7	0.9
Total Asset Turnover	0.4	0.3	0.3	0.1	0.1
Working Capital
Cash Conversion Cycle	213.0	268.0	358.0	409.0	487.0
Working Capital Days	-260.0	-15.0	-55.0	67.0	42.0

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Solvency +
Total Debt/Equity	2.5	1.6	2.3	0.8	0.8
Net Debt/Equity	2.2	1.5	2.2	0.8	0.7
Total Debt/Assets	0.3	0.3	0.5	0.4	0.3
Total Assets/Equity	9.4	5.1	4.4	2.3	2.4
Liquidity +
Current Ratio	0.5	0.9	1.0	1.3	0.8
Quick Ratio	0.3	0.5	0.6	0.7	0.5
Interest Coverage	9.0	19.9	15.0	4.5	2.3
Performance
Gross Margin	78.2	74.1	71.0	71.3	69.0
Operating Margin	32.2	26.4	28.9	23.8	22.8
Net Margin	13.6	9.5	11.0	2.4	2.4
Return +
Return on Equity	42.6	15.0	17.3	0.8	1.2
Pre-tax ROCE	15.6	8.0	9.6	2.1	3.2
Return on Assets	4.5	3.0	4.0	0.3	0.5
Pre-tax ROIC	19.8	9.0	8.4	2.2	3.1
Efficiency +
Days Payable	522.0	469.0	329.0	737.0	759.0
Days Inventory	572.0	626.0	513.0	720.0	496.0
Days Receivable	52.0	53.0	93.0	153.0	205.0
Fixed Asset Turnover	0.5	0.5	0.6	0.2	0.3
Total Asset Turnover	0.3	0.3	0.4	0.1	0.2
Working Capital
Cash Conversion Cycle	102.0	210.0	277.0	136.0	-58.0
Working Capital Days	-274.0	-68.0	8.0	102.0	-77.0

Ratios

Current ratio

Debt/equity ratio

Charges on assets

Bank wise

Charges

Citicorp International Limited (through its authorized representative Citibank N.A. India)

No. of Loans: 1

Total Amount : 6,808.8 cr

Axis Trustee Services Limited

No. of Loans: 1

Total Amount : 2,734.9 cr

Charge Holder	Amount	Date of creation/modification
Axis Trustee Services Limited	2,734.9 cr	30 Dec, 2024
Citicorp International Limited (through its authorized representative Citibank N.A. India)	6,808.8 cr	22 Nov, 2024

Charges

Citicorp International Limited (through its authorized representative Citibank N.A. India)

Axis Trustee Services Limited

Company Network

Companies connected through Directors

Name	Status	Paid up Capital	Common Directors	Address
BMR BUSINESS SOLUTIONS PRIVATE LIMITED	Active	8.5 L	1	Maharashtra
TAXAND ADVISORS PRIVATE LIMITED	Strike Off	1.0 L	1	Delhi
BMR GLOBAL SERVICES PRIVATE LIMITED	Active	1.0 L	1	Delhi
AVAANA CAPITAL ADVISORS LLP	Active	13,333.0	1	Maharashtra
RELIANCE PETROLEUM LIMITED	Amalgamated	4,500.0 Cr	1
INDOSTAR CAPITAL FINANCE LIMITED	Active	136.7 Cr	1	Maharashtra
INFOSYS LIMITED	Active	2,077.2 Cr	1	Karnataka
BIOCON LIMITED	Active	668.5 Cr	2	Karnataka
MYLAN LABORATORIES LIMITED	Active	48.7 Cr	1	Telangana
RAPIDUE TECHNOLOGIES PRIVATE LIMITED	Active	19.2 Cr	1	Telangana
BIOCON BIOPHARMACEUTICALS LIMITED	Amalgamated	17.6 Cr	2	Karnataka
CSEP RESEARCH FOUNDATION	Active	1.0 L	1	Delhi
BIOCON RESEARCH LIMITED	Active	5.0 L	2	Karnataka
SCIENCE GALLERY BENGALURU	Active	0.0	1	Karnataka
BIOFUSION THERAPEUTICS LIMITED	Active	5.0 L	1	Karnataka
GLENLOCH PROPERTIES LLP	Active	1.0 L	1	Karnataka
MAZUMDAR SHAW MEDICAL FOUNDATION	Active	1.0 L	1	Karnataka
KARNATAKA TECHNOLOGY AND INNOVATION MUSEUM FOUNDATION	Active	1.0 L	1
INNOVERSE FOUNDATION	Active	1.0 L	1
CLINIGENE INTERNATIONAL LIMITED	Amalgamated	5.0 L	1	Karnataka
BIOCON PHARMA LIMITED	Active	887.1 Cr	1	Karnataka
NARAYANA HRUDAYALAYA LIMITED	Active	204.4 Cr	2	Karnataka
TRENT LIMITED	Active	35.5 Cr	1	Maharashtra
BIOCON ACADEMY	Active	5.0 L	1	Karnataka
SYNGENE INTERNATIONAL LIMITED	Active	402.9 Cr	1	Karnataka
IMMUNEEL THERAPEUTICS PRIVATE LIMITED	Active	4.6 L	1	Karnataka
BIOCON BIOSPHERE LIMITED	Active	631.4 Cr	1	Karnataka
INVEST INDIA	Active	1.0 Cr	1	Delhi
MYNVAX PRIVATE LIMITED	Active	6.0 L	1	Karnataka
BIOLOGICAL E. LIMITED	Active	5.0 Cr	1	Telangana

Subsidiary Companies

Name	State / Country	Incorporation Year	Paidup Capital
Biocon Biologics UK Limited	United Kingdom	-	-
Biocon SDN BHD	Malaysia	-	-
Biocon Biologics Healthcare SDN BHD	Malaysia	-	-
Biocon Biologics Inc	United States	-	-
Biocon Biologics Do Brasil Ltda	Brazil	-	-
Biocon Biologics FZ LLC	United Arab Emirates	-	-
Biosimilar Collaborations Ireland Limited	Ireland	-	-
Biosilars Newco Limited, UK	United Kingdom	-	-
Biocon Biologics Germany GmbH, Germany	Germany	-	-
Biocon Biologics Canada Inc, Canada	Canada	-	-
Biocon Biologics France	France	-	-
Biocon Biologics Spain S.L.U, Spain	Spain	-	-
Biocon Biologics Switzerland AG, Switzerland	Swaziland	-	-
Biocon Biologics Belgium BV, Belgium	Belgium	-	-
Biocon Biologics Finland OY, Finland	Finland	-	-
Biocon Biologics Morocco S.A.R.L.A.U	Morocco	-	-
Biocon Biologics Greece SINGLE MEMBER P.C.	Greece	-	-
Biocon Biologics South Africa (Pty) Ltd.	South Africa	-	-
Biocon Biologics (Thailand) Co., Ltd.	Thailand	-	-
Biocon Biologics Philippines Inc.	Philippines	-	-
Biocon Biologics Italy S.r.l	Italy	-	-
Biocon Biologics Croatia LLC	Croatia	-	-
Biocon SDN BHD, Malaysia	Malaysia	-	-
Biocon Biologics Healthcare SDN BHD, Malaysia	Malaysia	-	-
Biocon Biologics Inc., USA	United States	-	-
Biosimilar Collaborations Ireland Limited, Ireland	Ireland	-	-
Biosimilars Newco Limited, UK	United Kingdom	-	-
Biocon Biologics France S.A.S, France	France	-	-
Biocon Biologics Switzerland AG, Switzerland	Switzerland	-	-
Biocon Biologics Belgium BV, Belgium	Belgium	-	-
Biocon Biologics Spain S.L.U, Spain	Spain	-	-
Biocon Biologics Finland OY, Finland	Finland	-	-
Biocon Biologics Greece SINGLE MEMBER P.C	Greece	-	-
Biocon Biologics (Thailand) Co., Ltd.	Thailand	-	-
Biocon Biologics Morocco S.R.L	Morocco	-	-
Biocon Biologics South Africa (Pty) Ltd.	South Africa	-	-
BIOCON BIOLOGICS PHILIPPINES INC.	Philippines	-	-
BIOCON BIOLOGICS ITALY S.R.L.	Italy	-	-
Biocon Biologics Croatia LLC	Croatia	-	-

Tofler Score

Very Good

Poor

Fair

Good

Very Good

Excellent

Risk

Severe Risk

VERY LOW INTEREST COVERAGE

Moderate Risk

RECEIVABLES DETERIORATING
LOW ROCE
CASH DETERIORATING

Low Risk

HIGH INVENTORY

About Tofler Score

Tofler Score measures the quality of performance and integrity of a company. It is dependent on three key factors - Sustainability, Governance, and Growth.

CIN

U24119KA2016PLC093936

PAN

AAGCB7796M

Incorporation

2016, 9.9 years

Company Email

Co.secretarybiologics@biocon.com

Paid up Capital

₹ 1,758.3 Cr

Authorised Capital

₹ 3,500.0 Cr

AGM

Jul 2025

Type

Public

Others

FAQ - BIOCON BIOLOGICS LIMITED

What is the incorporation date of BIOCON BIOLOGICS LIMITED?

The incorporation date of BIOCON BIOLOGICS LIMITED is 08 June, 2016

What is the authorized share capital of BIOCON BIOLOGICS LIMITED?

The authorized share capital of BIOCON BIOLOGICS LIMITED is INR ₹ 3,500.0 Cr.

What is the paid-up capital of BIOCON BIOLOGICS LIMITED?

The paid-up capital of BIOCON BIOLOGICS LIMITED is INR ₹ 1,758.3 Cr.

What is the registered address of BIOCON BIOLOGICS LIMITED?

The registered address of BIOCON BIOLOGICS LIMITED is Biocon House, Ground Floor, Tower-3, Semicon Park Electronic City, Phase - II, Hosur Road, Bangalore, Bengaluru, Karnataka, India, 560100 - 560100

What is the CIN number of BIOCON BIOLOGICS LIMITED?

The CIN number of BIOCON BIOLOGICS LIMITED is U24119KA2016PLC093936.

Smart Suggestions

Uttar Pradesh
Haryana
Jammu & Kashmir
Punjab
Goa
Madhya Pradesh
Kerala
Gujarat
Andhra Pradesh
Telangana
Blog Categories
Top Blog post
Financial Resources

Tofler, TWS Systems Private Limited and its officers respect the Intellectual Property Rights of all people. Tofler makes no claim of ownership or affiliation with any trademark (REGISTERED OR UNREGISTERED) that forms part of any Company/LLP name listed on this page. Trademarks, if any, listed on this page belong to... Read More

BIOCON BIOLOGICS LIMITED

Leave site?

Buy Dashboard using Credits

Just a Quick Check!

Buy Report or Plans

Dashboards

Company dashboard

Buy credits

View subscriptions

MCA Fillings

All financials

1 Year

PDF Reports

Financial report

Financial+Litigation report

Due diligence report

Choose number of credits to buy

₹ 449 + GST

Locations

Locations on Map

Filter (4)

Select Tags

Choose Location

People

Financial Highlights

Margins

Balance Sheet

Total assets

Profit & Loss

Revenue from operations

Ratios

Ratios

Charges on assets

Charges

Company Network